Albert Suheil Atallah-Yunes

Right before the end of the year! Out now @AjHematology We characterize the features and outcomes of an uncommonly encountered subtype of MALT lymphoma. Primary Breast MALT Lymphoma doi.org/10.1002/ajh.70…

#Hematology Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies #lymsm ashpublications.org/bloodadvances/…

New @AlbertYunes study: EBV+ polymorphic B-cell LPD (NOS) — first real-world cohort outside the transplant setting. 🧍‍♂️31 pts | Strong responses to rituximab ± immunosuppression reduction. 🧠 CNS cases can remit; rebiopsy crucial at relapse. 🔗 nature.com/articles/s4140…

In the largest cohort of #ALK+ LBCL to date, poor outcomes persisted despite intensified frontline chemotherapy or frontline ASCT. Integration of biologically informed therapies may have improved survival compared to historical data. #lymphoma doi.org/10.1002/ajh.70… @AlbertYunes

Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology : Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT onlinelibrary.wiley.com/doi/10.1002/aj…

Thrilled to share our latest study on secondary myeloid malignancies after CAR-T cell therapy led by Dr Francesca Sillito @uclh @drclaireroddie @Capt__Kirkwood @Haematologica haematologica.org/article/view/1…

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection | Blood Cancer Journal ⁦@MayoCancerCare⁩ nature.com/articles/s4140…

@DrRaulCordoba @MayoCancerCare Thanks so much Raul! Much appreciated!!

Kudos to @AlbertYunes @MayoCancerCare for such a great job!! Very proud of you #hematology #lymphoma #lymsm

Proteomic determinants of renal organ response in light-chain amyloidosis: Amyloid: Vol 0, No 0 #metrics-summary" target="_blank" rel="nofollow noopener">tandfonline.com/doi/metrics/10… @MattReesMD

#Hematology CODOX-M/IVAC-R vs DA-EPOCH-R in double-hit/triplehit #lymphoma patients aged 60 years or under | ⁦@Haematologica⁩ #lymsm haematologica.org/article/view/h…

Characteristics & outcomes of incidentally diagnosed large B cell #lymphoma. Patients have lower stage & IPI scores compared to symptomatic patients. Potential insight into what could be seen with multi-cancer early detection tests doi.org/10.1002/ajh.27… @AlbertYunes

Apply for #EHACRTH @EHA_Hematology “Clinical #Research Training in #Hematology” provides early-researchers with a unique, year-long training and mentoring experience. Apply by September 24, 15:00 CEST. eha.fyi/CRTH2025

#CRTH2024 has come to its end. Amazing scholars, high expertise faculty, extraordinary organization. Thanks to @EHA_Hematology for this outstanding #mentoring experience. Proud to be part of it. Looking forward to next year edition. Please, apply!! ehaweb.org/research/resea…

After a full day of working on projects, our #EHACRTH scholars took part in a teambuilding activity. CRTH is an opportunity to learn more than just clinical trials, but build new connections too (not to mention cooking skills). Learn more: eha.fyi/CRTH25 #YoungEHA

#EHA would like to congratulate this year's #EHACRTH scholars on completing the first workshop, offering insights into trial funding, working with the industry, patient safety and reporting, working with statisticians, and more. Learn more about CRTH: eha.fyi/CRTH25

@EHA_Hematology #EHACRTH “Clinical #Research Training in #Hematology” Workshop 1 has come to its end. Amazing progress done by scholars. Looking forward to seeing you all in Madrid at #EHA2024. Safe trips back home! #networking #mentoring

🎉Finally out🎉 Real-world results of CAR-T cell therapy for large B-cell lymphoma with CNS involvement ⁦@BloodAdvances⁩ #lymsm ashpublications.org/bloodadvances/…

CONGRESS #EHA2023 | @gilles_salles @MSKCancerCenter discusses a phase I/II trial of epocoritamab vs axi-cel in R/R DLBCL CAR-T naïve & eligible pts. There was no sig. difference in ORR or CR rates for CAR T-naive vs axi-cel. Results were similar for Ep vs Axi-cel #lymsm #lymphoma

Important future question: Venetoclax or Pirtobrutinib after a covalent BTKi? #EHA2023 #CLL #venetoclax #pirtobrutinib

Best part about #ASCO23 is connecting with med school friends! #LCSM #OncTwitter @UJ_MED @AlbertYunes @enaddawod